The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2021 | Genomic updates in the field of MPNs
Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the latest updates from genomic research in the field of myeloproliferative neoplasms (MPNs). Dr Rampal highlights the major drivers of MPN pathogenesis and their involvement in the JAK/STAT pathway, commenting on how these are being used to develop novel therapies and prognostic implications. In particular, Dr Rampal talks on the development of IDH1 and IDH2 inhibitors for the treatment of MPNs, highlighting a trial of ruxolitinib in combination with enasidenib (NCT04281498). This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Raajit Rampal, MD, PhD, discloses associations with Abbvie, CTI, Sierra Oncology, Novartis, BMS/Celgene, Stemline, Disc Medicine, Blueprint, Kartos, Pharmaessentia, Incyte, Jazz Pharmaceuticals.
